文献速递甲状腺疾病

纳秒脉冲场消融治疗良性甲状腺结节的首例人体临床可行性研究

First-in-Human Clinical Feasibility Study of Ablation of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation.
PubMed 文献 · Thyroid · 2025-08-21

该首例人体可行性试验评估纳秒脉冲场消融(nsPFA)经皮电极在超声引导下治疗良性甲状腺结节的安全性与有效性。研究分三队列:队列1在甲状腺切除术中消融后组织学评估,队列2在体消融用于剂量探索,队列3以治疗为目的消融整个结节。结果显示结节体积在2周、1个月和1年分别缩小48.2%、71.1%和85.8%,无严重不良事件,支持nsPFA的初步安全有效性。

要点

  • nsPFA可早期显著缩小良性甲状腺结节体积,1年缩小85.8%。
  • 最高消融设置(93 mJ/mm2)下出现短暂发音障碍(<24小时)。
  • 无严重不良事件,随访超声未见纤维化或瘢痕。

核心结论

  • 首例人体研究支持nsPFA电极系统治疗良性甲状腺结节的初步安全性和有效性。

研究设计与样本

  • 临床可行性试验(NCT06117085)分三队列:队列1为5例甲状腺切除术中消融后组织学评估,队列2为20例在体消融用于剂量探索,队列3为5例以治疗为目的消融整个结节。

主要发现

  • 队列1消融后平均消融区长度1.7 cm、宽度0.7 cm。
  • 队列2消融后90天平均消融区体积估计为2.7 cc(基于结节体积缩小)。
  • 队列2中最高消融设置(93 mJ/mm2)治疗的2例出现短暂发音障碍(<24小时)。
  • 队列3结节平均体积缩小:2周48.2%,1个月71.1%,1年85.8%。
  • 所有队列均无严重不良事件,随访超声未见纤维化或瘢痕。

临床怎么用

  • nsPFA作为微创非热消融方式,可能降低良性甲状腺结节治疗的主要并发症风险。
  • 患者通常可在治疗当天恢复日常活动。
  • 治疗后2周即可观察到结节体积缩小和症状缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Thyroid nodules are common in the general population, and most are benign. Thyroidectomy remains the most common treatment for symptomatic benign thyroid nodular disease. The objective of this study is to determine if a novel, cell-specific, nonthermal modality called nanosecond pulsed field ablation (nsPFA) can provide a safe and effective treatment for symptomatic thyroid nodules. Methods: In this clinical feasibility trial (NCT06117085), an nsPFA percutaneous electrode was used to ablate benign thyroid nodules under ultrasound guidance. In Cohort 1 (5 patients), ablations were created during a thyroidectomy procedure (treat-and-resect), so that initial ablation zone characterization could be assessed histologically. In Cohort 2 (20 patients), up to 4 isolated ablations were created in the in situ thyroid for dose-ranging and to allow for estimation of ablation zone volume. In Cohort 3 (5 patients), the entire nodule was ablated with therapeutic intent using multiple, overlapping ablations for resolution of symptoms. Results: For Cohort 1, the mean ablation zone measured 1.7 cm long by 0.7 cm wide post-ablation. For Cohort 2, the mean ablation zone was estimated to be 2.7 cc in volume at 90 days post-ablation (based on nodule size reduction from baseline). Transient dysphonia (<24 hours) was seen in two patients treated at the highest ablation setting (93 mJ/mm2). For Cohort 3, treated nodules had a mean volume reduction of 48.2% as early as 2 weeks, and 71.1% at 1 month and 85.8% at 1 year. Patients could typically resume normal activities on the same day. There was no transient dysphonia in this group. Noticeable volume reduction and relief of symptoms were seen as early as 2 weeks post-treatment. No fibrosis or scars were seen on follow-up ultrasounds. No serious adverse events were reported for any cohorts. Conclusions: This first-in-human study supports the initial safety/efficacy profile of the nsPFA electrode system in treating benign thyroid nodules. The minimally invasive and nonthermal nature of nsPFA energy has the potential to reduce risk of major complications in treatment of benign thyroid nodules as compared with thyroidectomy or thermal ablation and to improve healing through rapid reduction ofablated areas and lack of postprocedural scarring.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Spiezia S, Offi C, Misso C, et al. First-in-Human Clinical Feasibility Study of Ablation of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation. Thyroid. 2025. PMID: 40836795. doi:10.1177/10507256251372166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。